Shots:

• Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M- making a total deal value as $1.8B
• Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR & obtains full access to the Eligen SNAC technology platform- thus enabling Novo Nordisk to expand its portfolio of oral biologics across therapy areas
• The acquisition will provide Novo Nordisk full rights of the Eligen’s SNAC technology- which has been used under a 2007 license agreement to develop the first oral biologic- Rybelsus for T2D

­ Ref: Novo Nordisk | Image: SRX